The pharmaceutical companies Biogen and Eisai are developing a new drug to slow the rate of cognitive decline among patients with Alzheimer's disease, according to the New York Times. The drug, called lecanemab, reduced cognitive decline by 27 percent in a recent clinical trial. Previously, Biogen released the controversial drug Aduhelm, widely considered a commercial failure after Medicare restricted its coverage.
Related Posts
Rare varieties a feast for the apple lover
Two tips for apple adventurers: 1. Don’t judge an apple by its skin. Bright red means nothing, according to Rowan Jacobsen, author of Apples of Uncommon…
New treatment possibility for pulmonary fibrosis
A popular oral medicine used to treat type 2 diabetes shows promise in the treatment — and even reversal — of pulmonary fibrosis, according to Pulmonary…
Want to plant a tree yourself?
One Tree Planted, a Vermont-based nonprofit, operates on the simplest possible model: $1 plants one tree. Their Earth Month 2026 projects span six…